The role of inducible nitric oxide synthase in cardiac allograft rejection

Cardiovascular Research

Volumn 38, Issue 1, 1998, Pages 6-15

  Cannon, Paul J ^a,b   Yang, Xiaochun ^a   Szabolcs, Matthias J ^a   Ravalli, Stefano ^a   Sciacca, Robert R ^a   Michler, Robert E ^a  

^a The New York Presbyterian Hospital   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE;

ALLOGRAFT; CELLULAR IMMUNITY; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIUM CELL; ENZYME INDUCTION; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HEART PERFORMANCE; HEART TRANSPLANTATION; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW;

CELL DEATH; CYTOKINES; ENZYME INDUCTION; GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 0032051810     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00022-4     Document Type: Review

References (64)

1. [1] The registry of the International Society for Heart and Lung Transplantation: Tenth Official Report. J Heart Lung Transplant 1993; 12:543-548.
2. [2] Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987;19:19-25.
3. [3] Moncada S, Palmer RMJ, Higgs A. Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.
4. [4] Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-3064.
5. [5] Lowenstein C, Snyder C. Nitric oxide, a novel biologic messenger. Cell 1992;70:705-707.
6. [6] Balligand J-L, Cannon PJ. Nitric oxide synthases and cardiac muscle: autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997;17:1846-1858.
7. [7] Nathan C. Natural resistance and nitric oxide. Cell 1995;82:873-876.
8. [8] Wu CJ, Lovett M, Wong-Lee J, et al. Cytokine gene expression in rejecting cardiac allografts. Transplantation 1992;54:326-332.
9. [9] Yang X, Chowdhury N, Cai B, et al. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994;94:714-721.
10. [10] Worrall NK, Lazenby WD, Misko TP, Lin T-S, Rodi CP, Manning PT, Gilton RG, Williamson JR, Ferguson TB Jr. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995; 63-70.
11. [11] Worrall NK, Misko TP, Sullivan PM, Hui J-J, Ferguson TB Jr. Inhibition of inducible nitric oxide synthase attenuates established acute cardiac allograft rejection. Ann Thorac Surg 1996;62:378-385.
12. [12] Langrehr JM, Murase N, Markus PM, et al. Nitric oxide production in host-versus-graft and graft-versus-host reaction in the rat. J Clin Invest 1992;90:679-683.
13. [13] Lancaster JR Jr, Langrehr JM, Bergonia HA, Murase N, Simmons RI, Hoffman RA. EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. J Biol Chem 1992;267:10994-10998.
14. [14] Russell ME, Wallace AF, Wyner LR, Newell JB, Karnovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995;92:457-464.
15. [15] Lewis NP, Tsao PS, Rickenbacher PR, et al. Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 1996;93:720-729.
16. [16] Winlaw DS, Schyvens CG, Smythe GA, et al. Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation 1995;60:77-82.
17. [17] Akyurek LM, Fellstrom BC, Yan Z, Hansson GK, Funa K, Larsson E. Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic allografts. Am J Pathol 1996;149:1981-1990.
18. [18] Ravalli S, Albala A, Ming M, et al. Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease. Circulation 1998;in press.
19. [19] Buttery LDK, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes formation and activity of peroxynitrite. Lab Invest 1996;75:77-85.
20. [20] Aji W, Ravalli S, Szabolcs M, et al. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 1997;95:430-437.
21. [21] Albina JE, Cui S, Mateo RB, Rerichner JS. Nitric oxide mediated apoptosis in murine peritoneal macrophages. J Immunol 1993;150:5080-5085.
22. [22] Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-2274.
23. [23] Koglin J, Glysing-Jensen T, Mudgett JS, Russell M. Exacerbated transplant arteriosclerosis in iNOS-deficient mice: iNOS protects against immune-mediated intimal thickening. Circulation 1997;96:I-171. (Abstract).
24. [24] Barry WH. Mechanisms of immune-mediated myocyte injury. Circulation 1994;89:2421-2432.
25. [25] Russell ME, Wallace AF, Hancock WW, et al. Upregulation of cytokines associated with macrophage activation in the Lewis to F344 rat chronic cardiac rejection model. Transplantation 1995;59:572-578.
26. [26] Cai B, Roy DK, Sciacca R, Michler RE, Cannon PJ. Effects of immunosuppressive therapy on expression of inducible nitric oxide synthase (iNOS) during cardiac allograft rejection. Int J Cardiol 1995;50:243-251.
27. [27] Tian L, Noelle RJ, Lawrence DA. Activated T cells enhanced nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol 1995;25:306-309.
28. [28] Szabolcs MJ, Cannon PJ, Han A, et al. The distribution of CD40L and CD40 in native coronary atherosclerosis and transplant associated coronary artery disease: correlation of CD40 expression with the presence of intercellular adhesion molecules, activated NF-κB and presence of T lymphocytes. Submitted.
29. [29] Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. Transplantation 61:4-9.
30. [30] Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
31. [31] Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG. 8-Bromo cGMP reduces the myofilament response to calcium in intact cardiac myocytes. Circ Res 1994;74:970-978.
32. [32] Brady AJB, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992;263:H1963-H1966.
33. [33] Brady AJB, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993;265:H176-H182.
34. [34] Balligand JL, Ungureanu D, Pimental D, et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993;91:2314-2319.
35. [35] Balligand JL, Ungureanu-Longrois D, Simmons WW, et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. J Biol Chem 1994;269:27580-27588.
36. [36] Worrall NK, Pyo RT, Botney MD, et al. Inflammatory cell-derived NO modulates cardiac allograft contractile and electrophysiological function. Am Physiol Soc 1997; H28-H36.
37. [37] Paulus WJ, Kätner S, Pujadas P, Shah AM, Drexler H, Vanderleydan M. Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft. Circulation 1997;96:3436-3442.
38. [38] Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
39. [39] Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991;288:481-487.
40. [40] Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am Physiol Soc 1996; C1424-C1437.
41. [41] Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β. J Clin Invest 1995;95:677-685.
42. [42] Maino G, Joris I. Apoptosis, oncosis, and necrosis: an overview of cell death. Am J Pathol 1995;146:3-15.
43. [43] Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
44. [44] Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
45. [45] Yeh ETH. Editorial: life and death in the cardiovascular system. Circulation 1997; 782-786.
46. [46] Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or independent mechanisms. Cancer Res 1994;54:2462-2467.
47. [47] Szabolcs M, Michler RE, Yang X, et al. Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to induction of nitric oxide synthase. Circulation 1996;94:1665-1673.
48. [48] Pinsky DJ, Walif A, Szabolcs M, et al. Nitric oxide triggers programmed cell death (apoptosis) of adult rat ventricular myocytes in culture. Submitted.
49. [49] Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992;89:3030-3034.
50. [50] Burney S, Tamir S, Gal A, Tannenbarum SR. A mechanistic analysis of nitric oxide-induced cellular toxicity. Nitric Oxide: Biol Chem 1997;1:130-144.
51. [51] Szabolcs MJ, Ravalli S, Minanov O, Sciacca RR, Michler RE, Cannon PJ. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation 1998;65:804-812.
52. [52] Suzuki H, Wildhirl SM, Dudek RR, Narayan KS, Bailey GH, Bing RJ. Induction of apoptosis in myocardial infarction and its possible relationship to nitric oxide synthase in macrophages. Tissue Cell 1996;28:89-97.
53. [53] de Belder AJ, Radomski MW, Why HJF, et al. Nitric oxide synthase activities in human myocardium. Lancet 1993;341:84-85.
54. [54] Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-1094.
55. [55] Gottlieb RA, Berleson KO, Kloner RA, Bablor BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-1628.
56. [56] Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996;74:86-107.
57. [57] Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-1189.
58. [58] Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-1141.
59. [59] Yang X, Szabolcs M, Minanov O, et al. CNI-1493 prolongs survival and reduces myocyte loss, apoptosis and inflammation during rat cardiac allograft rejection. J Cardiovasc Pharmacol 1998;in press.
60. [60] Bianchi M, Ulrich P, Bloom O, et al. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammatory and endotoxin lethality. Mol Med 1995;1:254-266.
61. [61] Bianchi M, Bloom O, Raabe T, et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996;83:927-936.
62. [62] Messmer UK, Reed JC, Brüne B. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J Biol Chem 1996;271:20192-20197.
63. [63] Nicholson DW. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat Biotechnol 1996;14:297-301.
64. [64] Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996;184:2067-2072.